Vor Biopharma (VOR) Capital Expenditures (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Capital Expenditures data on file, last reported at $12000.0 in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $12000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $953000.0 (up 728.7% YoY), and the FY2025 annual result was $941000.0, up 310.92% from the prior year.
• Capital Expenditures eased to $12000.0 in Q1 2026 per VOR's latest filing, from $912000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $3.5 million in Q1 2022 and troughed at -$2.2 million in Q2 2022.
• A 5-year average of $80625.0 and a median of $10500.0 in 2024 frame the typical range for Capital Expenditures.
• On a YoY basis, Capital Expenditures climbed as much as 4155.56% in 2025 and fell as far as 1141.18% in 2025.
• A 5-year view of Capital Expenditures shows it stood at -$18000.0 in 2022, then surged by 138.89% to $7000.0 in 2023, then surged by 928.57% to $72000.0 in 2024, then soared by 1166.67% to $912000.0 in 2025, then plunged by 98.68% to $12000.0 in 2026.
• Business Quant data shows VOR's Capital Expenditures at $12000.0 in Q1 2026, $912000.0 in Q4 2025, and -$354000.0 in Q3 2025.